RecruitingNot ApplicableNCT05924646

CAlgary SAlt for POTS

CAlgary SAlt for Postural Orthostatic Tachycardia Syndrome Study


Sponsor

University of Calgary

Enrollment

50 participants

Start Date

May 7, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend \~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt diet over a period of 3 months. Participants will complete 3 in lab evaluations including autonomic function testing, tilt table testing, blood volume and urine sodium evaluation, plasma catecholamine measurements and and cytokine measurements.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Microcystalline Cellulose Capsules and Sodium Chloride Capsules for people with postural orthostatic tachycardia syndrome. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTSodium Chloride Capsules

Table salt in slow release capsules.

OTHERMicrocystalline Cellulose Capsules

Microcrystalline Cellulose Capsules (Placebo)


Locations(1)

University of Calgary

Calgary, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05924646


Related Trials